- T2 Biosystems Inc (NASDAQ:TTOO) executed a territory-exclusive distribution agreement in the Baltic Region, including Lithuania, Latvia, and Estonia.
- Under the terms of the agreement, T2 Biosystems will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance Panels, through the distributor.
- Related: T2 Biosystems Q2 Sales Below Expectations, Sticks To Annual Guidance.
- The execution of this exclusive distribution agreement further expands T2 Biosystems' commercialization.
- Epidemiology studies have shown that the Baltic region has a higher average incidence of sepsis per population than Western Europe.
- Introducing the T2Dx Instrument and sepsis panels into these countries will allow rapid detection of sepsis-causing pathogens and antibiotic resistance genes in hours instead of days.
- Price Action: TTOO shares are up 17.79% at $0.1053 during the premarket session on the last check Friday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
